MedTrace Logo

A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19

NCT04362059 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-09-29

No results posted yet for this study

Summary

Lung surfactant is present in the lungs. It covers the alveolar surface where it reduces the work of breathing and prevents the lungs from collapsing. In some respiratory diseases and in patients that require ventilation this substance does not function normally. This study will introduce surfactant to the patients lungs via the COVSurf Drug Delivery System

Conditions

Interventions

DEVICE

COVSurf Drug Delivery System

Device introduces surfactant to the patients lungs

OTHER

Standard of Care

Standard of care treatment for respiratory illness

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Michael P Grocott, MD · University Hospital Southampton NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-18
Primary Completion
2022-11-30
Completion
2023-01-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04362059 on ClinicalTrials.gov